253 related articles for article (PubMed ID: 19301612)
21. TURP in patients with biopsy-proven prostate cancer: sensitivity for cancer detection.
Bach T; Geavlete B; Pfeiffer D; Wendt-Nordahl G; Michel MS; Gross AJ
Urology; 2009 Jan; 73(1):100-4. PubMed ID: 18718643
[TBL] [Abstract][Full Text] [Related]
22. [Histological investigation of prostate cancer treated with hormonal agents].
Azumi M; Saga Y; Hashimoto H; Kakizaki H
Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867
[TBL] [Abstract][Full Text] [Related]
23. Transurethral microwave thermotherapy effectiveness in small prostates.
Larson BT; Mynderse L; Ulchaker J; Pulling C; Larson TR
Urology; 2006 Oct; 68(4):790-4. PubMed ID: 17070354
[TBL] [Abstract][Full Text] [Related]
24. [Hormone refractory prostate carcinoma metastasizes to the penis: a case report].
Kawahara T; Manabe Y; Asazuma A; Aoyama T; Hashimura T
Hinyokika Kiyo; 2009 Oct; 55(10):627-9. PubMed ID: 19938335
[TBL] [Abstract][Full Text] [Related]
25. Transurethral microwave thermotherapy of the prostate--evaluation with MRI and analysis of parameters relevant to outcome.
Vesely S; Müller M; Knutson T; Peeker R; Hellström M; Dahlstrand C
Scand J Urol Nephrol; 2008; 42(1):53-8. PubMed ID: 18210336
[TBL] [Abstract][Full Text] [Related]
26. Intraurethral prostate injections with mepivacaine epinephrine: effects on patient comfort, treatment time and energy consumption during high-energy transurethral microwave thermotherapy.
Knutson T; Johansson A; Damber JE; Fall M; Vesely S; Peeker R
Scand J Urol Nephrol; 2009; 43(4):300-6. PubMed ID: 19585385
[TBL] [Abstract][Full Text] [Related]
27. Editorial comment on: Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy.
de Reijke TM
Eur Urol; 2007 Dec; 52(6):1650-1. PubMed ID: 18074436
[No Abstract] [Full Text] [Related]
28. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
29. [Does transurethral resection cause metastatic dissemination of hormone treated prostatic cancer?].
Morote Robles J; Reig Ruiz C; Vila Barja J; Lorente Garin JA; López Pacios MA; de Torres Mateos JA; Soler Roselló A
Actas Urol Esp; 1993 Mar; 17(3):187-9. PubMed ID: 8506773
[TBL] [Abstract][Full Text] [Related]
30. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
31. Androgen deprivation therapy for precancerous lesions of the prostate.
Hull D; Bostwick DG
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
[TBL] [Abstract][Full Text] [Related]
32. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
33. Transurethral microwave thermotherapy: from evidence-based medicine to clinical practice.
Gravas S; Melekos MD
Curr Opin Urol; 2007 Jan; 17(1):12-6. PubMed ID: 17143105
[TBL] [Abstract][Full Text] [Related]
34. Photoselective vaporization combined with bipolar transurethral resection for the treatment of large prostate adenoma in high-risk patients.
Zhao Y; Chen J; Wang M; Sun P; Li L; Zhang H; Jin X
Saudi Med J; 2010 Dec; 31(12):1320-5. PubMed ID: 21135994
[TBL] [Abstract][Full Text] [Related]
35. [A case of brain metastasis associated with prostate cancer].
Soga N; Sugimura Y
Hinyokika Kiyo; 2004 Jan; 50(1):37-40. PubMed ID: 15032014
[TBL] [Abstract][Full Text] [Related]
36. Are monotherapy options reasonable for T3 prostate cancer?
Schellhammer PF; Lynch DF
Semin Urol Oncol; 1997 Nov; 15(4):207-14. PubMed ID: 9421447
[TBL] [Abstract][Full Text] [Related]
37. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
38. Incidence and factors predicting the detection of prostate cancer after transurethral resection of the prostate for clinically benign disease.
Bright EA; Manuel C; Goddard JC; Khan MA
Urol Int; 2009; 83(2):171-4. PubMed ID: 19752612
[TBL] [Abstract][Full Text] [Related]
39. High dose rate and external beam radiotherapy in locally advanced prostate cancer.
Viani GA; Pellizzon AC; Guimarães FS; Jacinto AA; dos Santos Novaes PE; Salvajoli JV
Am J Clin Oncol; 2009 Apr; 32(2):187-90. PubMed ID: 19307949
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up after triple treatment of prostate cancer stage pT3.
Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
